STAT Plus: In disappointment, Bristol pulls FDA application for Opdivo combination in lung cancer
MEL EVANS/AP
The company now says that it will need more data to explain outcomes in clinical trials, and wants to discuss data based on another test, for PD-L1.
.jpeg)
No hay comentarios:
Publicar un comentario